Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer
Farasat Kazmi(University of Oxford), Sarah P. Blagden(Churchill Hospital), Brian D Nicholson(Occidental Petroleum (United States)), Philip Heesen(Brigham and Women's Hospital), Nipun Shrestha(The University of Sydney), Stephen Booth(Royal Berkshire Hospital), Simon Lord(University of Oxford), Thomas Foord, David Dodwell(University of Oxford), Kheng‐Wei Yeoh(National Cancer Centre Singapore), Francesca Aroldi(Churchill Hospital)
Cited by 2
Related Papers
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
|Blood|2020|657
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
|The Lancet Oncology|2019|564
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
|The Lancet Infectious Diseases|2020|405